Geographic Atrophy Treatment segmentation by type separates products into biologic agents, small‑molecule drugs, and cell‑based therapies. Biologic agents, primarily complement inhibitors administered via intravitreal injection, dominate the market because they address the underlying inflammatory cascade that drives atrophy progression. Small‑molecule drugs, often oral or topical, contribute a modest share; their lower delivery cost is offset by limited efficacy data in late‑stage trials. Cell‑based therapies, still experimental, represent a nascent niche focused on retinal pigment epithelium regeneration. Quantitatively, biologics account for roughly 55 % of total revenue, small molecules 30 %, and cell‑based approaches 15 %. This distribution reflects both regulatory approvals and pipeline maturity, indicating that biologics are the primary growth engine while the other types provide complementary avenues for diversification. Pricing structures for biologics are typically premium, supported by robust payer coverage in high‑income regions, whereas small‑molecule products benefit from broader geographic accessibility due to lower unit costs. Cell‑based interventions, despite their limited current market share, attract significant venture capital, suggesting a potential shift in the segment composition over the next decade.
